TransMedics Group (NASDAQ:TMDX) Price Target Raised to $174.00

TransMedics Group (NASDAQ:TMDX) had its price target increased by Needham & Company LLC from $166.00 to $174.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

TMDX has been the topic of a number of other research reports. Morgan Stanley upped their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Canaccord Genuity Group upped their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, February 14th. Finally, Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $150.67.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $145.26 on Wednesday. The company has a market cap of $4.98 billion, a price-to-earnings ratio of 29.64 and a beta of 2.06. TransMedics Group has a 1 year low of $62.07 and a 1 year high of $156.00. The stock’s 50 day simple moving average is $133.80 and its two-hundred day simple moving average is $126.44. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 7.13.

Insider Activity

In related news, Director David Weill sold 5,000 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the sale, the director directly owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This represents a 29.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This trade represents a 5.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Hedge funds have recently bought and sold shares of the business. Marshall Wace LLP lifted its position in shares of TransMedics Group by 258.7% during the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after purchasing an additional 394,340 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of TransMedics Group by 50.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock worth $117,506,000 after purchasing an additional 322,353 shares during the last quarter. Two Sigma Investments LP increased its stake in TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after buying an additional 223,409 shares during the period. Wellington Management Group LLP lifted its holdings in TransMedics Group by 100.5% during the 4th quarter. Wellington Management Group LLP now owns 433,321 shares of the company’s stock valued at $52,713,000 after buying an additional 217,180 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in TransMedics Group by 43.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock valued at $69,338,000 after buying an additional 171,810 shares during the period. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.